Financhill
Buy
64

BSX Quote, Financials, Valuation and Earnings

Last price:
$97.14
Seasonality move :
6.11%
Day range:
$94.85 - $96.64
52-week range:
$65.52 - $107.17
Dividend yield:
0%
P/E ratio:
76.30x
P/S ratio:
8.46x
P/B ratio:
6.47x
Volume:
8.1M
Avg. volume:
8M
1-year change:
44.41%
Market cap:
$140.7B
Revenue:
$16.7B
EPS (TTM):
$1.25

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.33% $115.62
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.26
HAE
Haemonetics
$352.9M $1.17 -3.69% 205.28% $96.80
JNJ
Johnson & Johnson
$22.4B $2.01 1.26% 97.05% $169.07
RMD
ResMed
$1.3B $2.31 7.21% 15.65% $269.38
SYK
Stryker
$6.4B $3.87 8.28% 33.5% $424.43
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BSX
Boston Scientific
$95.37 $115.62 $140.7B 76.30x $0.00 0% 8.46x
ABT
Abbott Laboratories
$129.89 $136.26 $225.3B 16.98x $0.59 1.73% 5.41x
HAE
Haemonetics
$65.93 $96.80 $3.3B 25.96x $0.00 0% 2.46x
JNJ
Johnson & Johnson
$162.99 $169.07 $392.8B 28.15x $1.24 3.04% 4.45x
RMD
ResMed
$219.72 $269.38 $32.3B 25.94x $0.53 0.94% 6.58x
SYK
Stryker
$363.66 $424.43 $138.8B 46.86x $0.84 0.89% 6.21x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
HAE
Haemonetics
57.46% 1.072 31.23% 2.10x
JNJ
Johnson & Johnson
33.88% 0.530 10.52% 0.86x
RMD
ResMed
11.35% 0.169 2% 1.74x
SYK
Stryker
39.72% 1.452 10.13% 1.11x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
HAE
Haemonetics
$193.5M $59M 6.54% 14.16% 16.94% $35.2M
JNJ
Johnson & Johnson
$15.4B $3.8B 13.3% 19.98% 17.87% $4.8B
RMD
ResMed
$751.3M $417.2M 21.74% 25.56% 32.54% $285.2M
SYK
Stryker
$4.2B $1.6B 9.04% 15.22% 24.21% $1.7B

Boston Scientific vs. Competitors

  • Which has Higher Returns BSX or ABT?

    Abbott Laboratories has a net margin of 12.41% compared to Boston Scientific's net margin of 84.1%. Boston Scientific's return on equity of 8.96% beat Abbott Laboratories's return on equity of 32.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
  • What do Analysts Say About BSX or ABT?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Abbott Laboratories has an analysts' consensus of $136.26 which suggests that it could grow by 4.91%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    ABT
    Abbott Laboratories
    13 6 0
  • Is BSX or ABT More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.

  • Which is a Better Dividend Stock BSX or ABT?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.73% to investors and pays a quarterly dividend of $0.59 per share. Boston Scientific pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or ABT?

    Boston Scientific quarterly revenues are $4.6B, which are smaller than Abbott Laboratories quarterly revenues of $11B. Boston Scientific's net income of $566M is lower than Abbott Laboratories's net income of $9.2B. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Abbott Laboratories's PE ratio is 16.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 5.41x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.46x 76.30x $4.6B $566M
    ABT
    Abbott Laboratories
    5.41x 16.98x $11B $9.2B
  • Which has Higher Returns BSX or HAE?

    Haemonetics has a net margin of 12.41% compared to Boston Scientific's net margin of 10.76%. Boston Scientific's return on equity of 8.96% beat Haemonetics's return on equity of 14.16%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    HAE
    Haemonetics
    55.53% $0.74 $2.1B
  • What do Analysts Say About BSX or HAE?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Haemonetics has an analysts' consensus of $96.80 which suggests that it could grow by 46.82%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    HAE
    Haemonetics
    3 1 0
  • Is BSX or HAE More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.430, suggesting its less volatile than the S&P 500 by 57.014%.

  • Which is a Better Dividend Stock BSX or HAE?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BSX or HAE?

    Boston Scientific quarterly revenues are $4.6B, which are larger than Haemonetics quarterly revenues of $348.5M. Boston Scientific's net income of $566M is higher than Haemonetics's net income of $37.5M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Haemonetics's PE ratio is 25.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 2.46x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.46x 76.30x $4.6B $566M
    HAE
    Haemonetics
    2.46x 25.96x $348.5M $37.5M
  • Which has Higher Returns BSX or JNJ?

    Johnson & Johnson has a net margin of 12.41% compared to Boston Scientific's net margin of 15.24%. Boston Scientific's return on equity of 8.96% beat Johnson & Johnson's return on equity of 19.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    JNJ
    Johnson & Johnson
    68.35% $1.41 $108.1B
  • What do Analysts Say About BSX or JNJ?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.73%. Given that Boston Scientific has higher upside potential than Johnson & Johnson, analysts believe Boston Scientific is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    JNJ
    Johnson & Johnson
    7 13 0
  • Is BSX or JNJ More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

  • Which is a Better Dividend Stock BSX or JNJ?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.04% to investors and pays a quarterly dividend of $1.24 per share. Boston Scientific pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or JNJ?

    Boston Scientific quarterly revenues are $4.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Boston Scientific's net income of $566M is lower than Johnson & Johnson's net income of $3.4B. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Johnson & Johnson's PE ratio is 28.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.46x 76.30x $4.6B $566M
    JNJ
    Johnson & Johnson
    4.45x 28.15x $22.5B $3.4B
  • Which has Higher Returns BSX or RMD?

    ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    RMD
    ResMed
    58.6% $2.34 $5.9B
  • What do Analysts Say About BSX or RMD?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 22.6%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    RMD
    ResMed
    7 7 1
  • Is BSX or RMD More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

  • Which is a Better Dividend Stock BSX or RMD?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or RMD?

    Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.46x 76.30x $4.6B $566M
    RMD
    ResMed
    6.58x 25.94x $1.3B $344.6M
  • Which has Higher Returns BSX or SYK?

    Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
    SYK
    Stryker
    64.85% $1.41 $34.2B
  • What do Analysts Say About BSX or SYK?

    Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 16.71%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    BSX
    Boston Scientific
    23 4 0
    SYK
    Stryker
    13 9 0
  • Is BSX or SYK More Risky?

    Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

  • Which is a Better Dividend Stock BSX or SYK?

    Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.89% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BSX or SYK?

    Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Stryker's PE ratio is 46.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 6.21x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BSX
    Boston Scientific
    8.46x 76.30x $4.6B $566M
    SYK
    Stryker
    6.21x 46.86x $6.4B $546M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Tesla Stock: The Bear Case
Tesla Stock: The Bear Case

The recent stock market drop has been a punishing time…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Alerts

Sell
5
CABO alert for Mar 14

Cable One [CABO] is down 3.97% over the past day.

Sell
38
ADBE alert for Mar 14

Adobe [ADBE] is up 4.43% over the past day.

Sell
29
CAR alert for Mar 14

Avis Budget Group [CAR] is up 11.68% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock